100% satisfaction guarantee Immediately available after payment Both online and in PDF No strings attached
logo-home
Previously searched by you
Previously searched by you
logo
US RAC Review Questions RAPS Modules Questions and Answers 100% Pass $12.49   Add to cart
Quickly navigate to
Preview
  2.  
  3. Prep Tests
  4.  
  5. Prep Tests

Exam (elaborations)

US RAC Review Questions RAPS Modules Questions and Answers 100% Pass
 1 view  0 purchase
  • Course
  • Prep Tests
  • Institution
  • Prep Tests

US RAC Review Questions RAPS Modules Questions and Answers 100% Pass In which situation is an IND not required? A) You intend to conduct a clinical trial with an investigational new drug B) You intend to conduct a clinical trial with an approved drug to support a marketing application for a ne...

[Show more]

Preview 4 out of 35  pages

Document information

  • November 11, 2024
  • 35
  • 2024/2025
  • Exam (elaborations)
  • Questions & answers

Subjects

  • us rac review questions raps modules questions and

Written for

  • Prep Tests
  • Prep Tests

Seller

avatar-seller
OliviaWest

Reviews received

Content preview

Copyright © OLIVIAWEST2024/2025 ACADEMIC YEAR. ALL RIGHTS RESERVED




US RAC Review Questions RAPS Modules

Questions and Answers 100% Pass


In which situation is an IND not required?




A) You intend to conduct a clinical trial with an investigational new drug


B) You intend to conduct a clinical trial with an approved drug to support a marketing application for a

new indication


C) You intend to collect blood samples from subjects to look for biomarkers or pharmacogenetic

information


D) You intend to conduct a clinical trial using 2 of your approved drugs in a new combination -

ANSWER✔✔-C) You intend to collect blood samples from subjects to look for biomarkers or

pharmacogenetic information


In the clinical development plan for an investigational antihypertensive drug, which of the following

studies would typically be conducted first:




A) 1 month repeat dose toxicology study


B) Single dose escalation PK study in healthy volunteers


C) Multiple dose PK study in healthy volunteers


Copyright ©Stuvia International BV 2010-2024 Page 1/35

, Copyright © OLIVIAWEST2024/2025 ACADEMIC YEAR. ALL RIGHTS RESERVED


D) Single dose escalation study in hypertensive patients - ANSWER✔✔-B) Single dose escalation PK study

in healthy volunteers


A sponsor must report an unexpected, fatal or life-threatening experience believed to be associated with

an unapproved drug/biologic:




A) to FDA, investigators and IRBs within 7 calendar days


B) to FDA and investigators within 7 calendar days


C) to FDA within 14 calendar days


D) to FDA and investigators within 7 working days - ANSWER✔✔-B) to FDA and investigators within 7

calendar days


Which of the following is a covered study as defined under Financial Disclosure regulations:




A) Phase I dose escalation study


B) Phase I/II Pharmacokinetic Study


C) A large open label safety study conducted at a large number of study sites


D) Phase III pivotal study - ANSWER✔✔-D) Phase III pivotal study


Your company is developing a product to treat a serious and life threatening disease. A clinically

meaningful, well established primary endpoint will be used in the pivotal studies. Which regulatory

strategy might you select prior to commencing Phase 3 studies?




Copyright ©Stuvia International BV 2010-2024 Page 2/35

, Copyright © OLIVIAWEST2024/2025 ACADEMIC YEAR. ALL RIGHTS RESERVED


A) Request Special Protocol Assessment


B) Request Fast Track Designation


C) Request Priority Review


D) Approval under Subpart H, Accelerated Approval of New Drugs for Serious or Life Threatening

Illnesses - ANSWER✔✔-A) Request Special Protocol Assessment


As a regulatory affairs professional, you are responsible for developing the content of an information

package for a Type B meeting with FDA. Your primary objective is to:




A) Reach consensus on content from contributing team members


B) Ensure content is sufficient to support meeting objective(s) and questions to FDA


C) Provide appropriate preclinical summary


D) Provide appropriate clinical summary - ANSWER✔✔-B) Ensure content is sufficient to support

meeting objective(s) and questions to FDA


You, a regulatory affairs professional, are assessing the information to be submitted in support of a

marketing application for a new dosage form for a listed drug. You lack right of reference to one key

preclinical report. Which type of application will you prepare for submission?




A) 505 (b) (1)


B) 505 (b) (2)


C) 505 (j)

Copyright ©Stuvia International BV 2010-2024 Page 3/35

, Copyright © OLIVIAWEST2024/2025 ACADEMIC YEAR. ALL RIGHTS RESERVED


D) PMA - ANSWER✔✔-B) 505 (b) (2)


8) If FDA were to invoke the Application Integrity Policy, which of the following is a possible outcome?




A) Defer review of pending application(s)


B) "File" a marketing application at the 60 day review


C) Grant a waiver or deferral for pediatric clinical study


D) Approve a marketing application - ANSWER✔✔-A) Defer review of pending application(s)


9) Which of the following supplements to an approved NDA/BLA must be approved by FDA prior to

distributing product made using the change?




A) Make change(s) to comply with USP


B) Change in the technical grade of an excipient, same


specifications and use


C) Add a warning statement to prescribing information


D) Process change outside the validated range - ANSWER✔✔-D) Process change outside the validated

range


10) Which of the following products would not be regulated by CDER?




A) Therapeutic proteins


Copyright ©Stuvia International BV 2010-2024 Page 4/35

The benefits of buying summaries with Stuvia:

Guaranteed quality through customer reviews

Guaranteed quality through customer reviews

Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.

Quick and easy check-out

Quick and easy check-out

You can quickly pay through credit card or Stuvia-credit for the summaries. There is no membership needed.

Focus on what matters

Focus on what matters

Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!

Frequently asked questions

What do I get when I buy this document?

You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.

Satisfaction guarantee: how does it work?

Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.

Who am I buying these notes from?

Stuvia is a marketplace, so you are not buying this document from us, but from seller OliviaWest. Stuvia facilitates payment to the seller.

Will I be stuck with a subscription?

No, you only buy these notes for $12.49. You're not tied to anything after your purchase.

Can Stuvia be trusted?

4.6 stars on Google & Trustpilot (+1000 reviews)

77254 documents were sold in the last 30 days

Founded in 2010, the go-to place to buy study notes for 14 years now

Start selling
$12.49
  • (0)
  Add to cart